The attempt to combat rare diseases is a challenging task that exemplifies how the pharmaceutical industry addresses unmet medical needs. This Award will recognize the efforts of an individual, team, or company that demonstrated excellence while developing a drug intended to treat rare diseases. The judges will be looking for a drug development program or trial with the largest potential impact in the rare disease space. Outstanding patient centric processes and innovation in study conduct to overcome the various obstacles of rare disease drug development will also earn high marks.

WHO CAN ENTER

To be eligible, drug development activities must have taken place between January 2024 – February 2025. Entrants must have played a role in drug development and/or trial conduct, and all joint parties must be disclosed in the application.

To enter this category, please provide the following:

• The name of the individual, team, or company, including an outline of their role(s).
• Details of the drug development program or clinical trial, i.e., rare disease(s) being targeted, name of drug(s), trial name(s) (title, protocol ID, trial identifier), phase, patient segment(s) studied, and sponsor(s).
• Provide evidence of the impact that the drug has had, or potentially could have, on the patient population and addressing unmet medical needs.
• Describe any unique strategies used to ensure successful study execution within this challenging space, such as trial design, patient centric processes (i.e., close engagement of patient advocacy groups), innovative patient recruitment methods in identifying potential trial participants, or study planning strategies (i.e., use of surrogate markers or original tools and approaches to gather key clinical data).
• If available, please provide documentation (URL) in support of the achievements described.

ENTER NOW

This Award will recognize an early phase research project that met or surpassed its objectives on a range of key performance indicators. The entrant should show that the successful completion of the program was material in enabling the sponsor to advance its drug to the next development phase either on or ahead of schedule and/or keeping within its development budget.

WHO CAN ENTER

To be eligible, results for the study or program under nomination must have been released between January 2024 – February 2025. Entrants must have played a role in the early phase research, and all joint parties must be disclosed in the application.

To enter this category, please provide the following:

• Full details of the project; i.e. project name (i.e. name of drug candidate or trial title), phase of development, target indication and population studied (if applicable), sponsor(s), and the primary drug(s) tested.
• Summarize the major findings of the study, such as in vitro/in vivo results or primary/co-primary and main secondary endpoints.
• What were the main milestones and deadlines for the preclinical or Phase I study? Please supply evidence of how these were met or surpassed.
• How did this study enable advancement of the drug to the next development stage?
• If available, please provide documentation (URL) of trial results; i.e. press release, investor presentation, conference abstract/presentation, clinical study report synopsis or other publication.

ENTER NOW

Enhancing the diversity of clinical trial populations is critical to achieving equity in healthcare and improving health outcomes in our most vulnerable populations. Historically, clinical trial populations have been rather homogenous, and treatment effect and patient outcomes observed in a trial setting may have limited applicability to the larger ‘real world’ population.

This Award will recognize a company, team or individual who has demonstrated exceptional initiative in promoting diversity and inclusion of underrepresented populations within a clinical trial or drug development program. The entrant should describe the activities/strategies implemented and the impact they had on patient enrolment. Activities ranging from patient-focused study design, use of technology, awareness and recruitment campaigns, or other creative and innovative approaches will be considered. Evidence of the impact these activities/strategies had on recruitment should also be included.

WHO CAN ENTER

To be eligible, the initiatives undertaken must have been activated January 2024 – February 2025. Entrants must have played a role in the design, launch or execution of the plans, and all joint parties must be disclosed in the application.

To enter this category, please provide the following:

• Full details of the project, i.e., project name (i.e., name of drug candidate or trial title), phase of development, target indication and population studied (if applicable), sponsor(s), and the primary drug(s) tested.
• What specific strategies/activities were undertaken? At what point in the study were they deployed?
• Describe the impact the strategies/activities had on study recruitment. Please share any relevant metrics used for measuring impact.
• If available, please provide documentation (URL) of trial recruitment campaign or any other publicly available sources that illustrate the strategies/activities undertaken.

ENTER NOW

The winning biotech research team will have made significant contributions in advancing a new therapy through one or more clinical phases. The judges will be looking to reward the high performing team that has been most successful in reaching its goals, adopted effective working practices, achieved major milestones within expected timelines, and contributed to the advancement of new therapies.

WHO CAN ENTER

To be eligible, the core project for the nominated team must be ongoing or completed between January 2024 – February 2025. Entrants must have played a role in the core project for the product.

To enter this category, please provide the following:

• The company’s name, the team being entered and basic details of its core project.
• What was the greatest achievement of the team during the qualifying period?
• How did all members/functions of the team work together to achieve its goals?
• How does the achievement contribute to advancing new therapies to market?
• What work practices has the team adopted to support the success of the product’s development?
• If you believe that this team is particularly outstanding, but for reasons not covered in the questions above, please give relevant details.

ENTER NOW

The winning pharma research team will have made significant contributions in advancing a new therapy through one or more clinical phases. The judges will be looking to reward the high performing team that has been most successful in reaching its goals, adopted effective working practices, achieved major milestones within expected timelines, and contributed to the advancement of new therapies.

WHO CAN ENTER

To be eligible, the core project for the nominated team must be ongoing or completed between January 2024 – February 2025. Entrants must have played a role in the core project for the product.

To enter this category, please provide the following:

• The company’s name, the team being entered and basic details of its core project.
• What was the greatest achievement of the team during the qualifying period?
• How did all members/functions of the team work together to achieve its goals?
• How does the achievement contribute to advancing new therapies to market?
• What work practices has the team adopted to support the success of the product’s development?
• If you believe that this team is particularly outstanding, but for reasons not covered in the questions above, please give relevant details.

ENTER NOW

This Award will be presented to two or more organizations who have set a new benchmark in partnering through collaborative clinical trial activity that took place in 2024/25. Partnerships could take place between multiple pharmaceutical and/or biotech companies or between a pharmaceutical and/or biotech company and a research institute, non-profit, or cooperative group.

WHO CAN ENTER

To be eligible, the collaborative clinical trial activity in question must be ongoing or completed between January 2024 – February 2025. Entrants must have played a role in the collaborative clinical trial activity, and all joint parties must be disclosed in the application.

To enter this category, please provide the following:

• Provide the names of organizations involved and basic details of the partnership.
• Why was the partnership novel?
• How does this partnership set a new benchmark for other deals?
• How has partnership achieved an outcome that would not have been possible if partnership had not been created?
• If available, please provide documentation in support of the achievements described.

ENTER NOW

This Award will be presented to two or more organizations who have set a new benchmark in partnering through collaborative clinical trial activity that took place in 2024/25. Partnerships for this award must be between a pharmaceutical or biotech company and a contract research organization.

WHO CAN ENTER

To be eligible, the collaborative clinical trial activity in question must be ongoing or completed between January 2024 – February 2025. Entrants must have played a role in the collaborative clinical trial activity, and all joint parties must be disclosed in the application.

To enter this category, please provide the following:

• Provide the names of organizations involved and basic details of the partnership.
• Why was the partnership novel?
• How does this partnership set a new benchmark for other deals?
• How has partnership achieved an outcome that would not have been possible if partnership had not been created?
• If available, please provide documentation (URL) in support of the achievements described.

ENTER NOW

Clinical trials are high risk, expensive, resource-intense undertakings that present significant challenges to any company. This award will recognize a pharma/biotech company that has developed creative and innovative approaches to the formidable challenges that clinical trials present.

Solutions may include innovations in designing any clinical trial related activity including patient recruitment and engagement or protocol design elements such as remote/decentralized trials, master protocols, complex adaptive/Bayesian trials, external controls, and other novel clinical trial designs. Solutions must have been developed or applied between January 2024 – February 2025.

WHO CAN ENTER

Companies wishing to enter must have been involved in the clinical trial, and all parties to any joint development activities must be disclosed in the application.

To enter this category, please provide the following:

• The name of the company and the innovative solution.
• Specify the date of first implementation.
• Outline the key features and benefits of the innovative design, and the impact it had on the study timeline, costs, or quality. Where applicable, include cost and/or time savings data to support any claims.
• What problems does this innovative approach solve and what is novel about it?
• If possible, please provide additional supporting documentation (process flow chart, video, etc.).

ENTER NOW

With this award, we are looking to recognize the accomplishments of an exceptional individual with a consistent history of significant contributions to the biopharma research and development field. This award will go to someone who has had a distinguished career in R&D or clinical research, working at a pharmaceutical company, biotech or research institution. The nominee should have a history of successful projects that have had a positive impact on human health. Metrics can include scientific publications and citations; patents and involvement in innovation; involvement in clinical trials and drug approvals; contributions to the development of future scientists and leaders in the field through mentorship, training programs, and leadership roles in professional organizations.

Nominees may be retired or still working either at a pharma company, biotech or research institution.

All nominations must include:

• The nominee’s name and job title
• The company name (if applicable)
• If an investigator, the names of major clinical trials the nominee has been involved in
• Your contact details
• The contact details of the nominee
• A summary of up to 750 words of why your nominee is worthy of receiving the Industry Achievement Award

ENTER NOW

This Award will recognize the clinical trial which reported results that had the greatest impact and is expected to lead to an advance in healthcare. The judges will be looking to reward the clinical trial with the largest commercial impact, highest impact on patient population, the greatest disruption in a market, or the advancement of clinical trial design. This might include the first demonstration of a clear clinical effect for a new drug in an area of unmet medical need, a pivotal study of a new drug with a breakthrough mechanism of action, or a major study of a potential new or expanded indication for an already marketed product.

WHO CAN ENTER

To be eligible, results for the study under nomination must have been presented in the public domain between January 2024 – February 2025. Entrants must have played a role in the clinical study, and all joint parties must be disclosed in the application.

To enter this category, please provide the following:

• Full details of the study; i.e. trial name (title, protocol ID, trial identifier), phase, disease type and patient segment(s) studied, sponsor(s), and the primary drug(s) tested.
• Summarize the major findings of the study, including all primary/co-primary and main secondary endpoints, and safety endpoints.
• Provide evidence supporting uniqueness and advancement of knowledge in an area of unmet medical need or clinical trial design.
• How do these findings represent a potential leap forward in therapy?
• Documentation (URL) of publicly available trial results required; i.e. press release, conference abstract/presentation, clinical study report synopsis or other publication.

ENTER NOW

Across the biopharmaceutical industry, companies make great efforts to support patients and communities. This Award will recognize a company’s efforts to improve their community, either through work with a patient advocacy organization, a direct effort within a community, scholarship or other funding programs or other forms of social investment. These activities could involve disease education and awareness initiatives, efforts to improve patient engagement and amplify patient voices, or efforts to improve health equity through education, outreach, charity initiatives, sponsorship or direct community investment.

• The nominee(s) must be currently employed by a pharmaceutical or biotech company
• The nominee(s) should have demonstrated significant efforts in reducing patient burden, championing patient communities or causes
• The nominee(s) should describe how their actions have met the needs of a patient group or community
• Provide relevant communication/education material for judges to review

ENTER NOW